NCT04396340 : A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1592 In Patients With Solid Tumors Likely to Express NaPi2b

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

One/TwoPhase One/Two

18-95Age 18-95

Advanced CancersCancer LocationMulti-Cancer
Trial

Systemic therapy,Treatment | Female reproductive organs,LungFallopian tube,Lung,Non-Small Cell Lung Cancer,Ovary,Peritoneal

Trial Overview Read MoreRead more

This phase I/II trial is evaluating the safety and clinical activity of a new intravenous cancer treatment for people with high grade serous ovarian cancer or non-small cell lung cancer.
 

This trial is treating patients with high grade serous ovarian cancer or non-small cell lung cancer.

This is a systemic therapy trial.

You may be able to join this trial if:

  • Your cancer has spread to other parts of the body.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1592 In Patients With Solid Tumors Likely to Express NaPi2b

Commercial Sponsor

Mersana Therapeutics, in collaboration with IQVIA Biotech

Summary

This is a dose escalation and expansion trial, consisting of two parallel cohorts of patients (high grade serous ovarian cancer and non-small cell lung cancer). In the dose escalation part of the trial, increasing doses of XMT-1592 will be administered to groups of patients over time, until the maximum tolerated dose is achieved. In the dose expansion (confirmation) part of the trial, new groups of patients will receive XMT-1592 at the maximum tolerated dose to confirm the recommended Phase 2 dose. XMT-1592 will be administered once every 21 days.

Recruiting Hospitals Read MoreRead more

PCCTU (Parkville Cancer Clinical Trials Unit) *
Parkville
Enquiries Line Coordinator
clinicaltrials.enquiries@petermac.org
03 8559 7456 (9am-2pm, Mon-Fri)

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next